JLE

Innovations & Thérapeutiques en Oncologie

MENU

Reducing the risk of relapse in patients with localised breast cancer over-expressing HER2 Volume 7, issue 2, March-April 2021

Figures


  • Figure 1

  • Figure 2

  • Figure 3

  • Figure 4

  • Figure 5

  • Figure 6

Tables

Author
1 Hôpital Lyon Sud
Institut de cancérologie des Hospices civils de Lyon (IC-HCL)
Service d’oncologie
3, quai des Célestins
69002 Lyon
France
2 Université Claude Bernard Lyon 1
43, boulevard du 11 Novembre 1918 69100 Villeurbanne
France
* Tirés à part

The treatment of HER2-overexpressing localized breast cancer is undergoing significant transformation. While trastuzumab has significantly improved the prognosis for these patients, almost 30% will have a relapse within 11 years. With such a high recurrence rate, optimization of HER2 pathway inhibition at an early stage is mandatory. HER2-targeted therapies with a favourable impact at the metastatic stage have been evaluated in Phase II and III trials, and have demonstrated superiority regarding complete response rate or disease-free survival, compared to a treatment with trastuzumab alone.